Prescribers' Satisfaction with Delivering Medications for Opioid Use Disorder

Overview

Journal Subst Abuse Treat Prev Policy

Publisher Biomed Central

Specialty Psychiatry

Date 2021 Oct 19

PMID 34663379

Authors

Hannah K Knudsen

Randy Brown

Nora Jacobson

Julie Horst

Jee-Seon Kim

Hanna Kim

Lynn M Madden

Eric Haram

Todd Molfenter

Affiliations

Soon will be listed here.

Abstract

Background: Expanding access to medications for opioid use disorder (MOUD), such as buprenorphine and extended release (XR) naltrexone, is critical to addressing the US opioid epidemic, but little is known about prescriber satisfaction with delivering these two types of MOUD. The current study describes the satisfaction of prescribers delivering buprenorphine and XR-naltrexone while examining whether satisfaction is associated with current patient census and organizational environment.

Methods: As part of a cluster randomized clinical trial (RCT) focused on expanding access to medication for opioid use disorder, 41 MOUD prescribers in Florida, Ohio, and Wisconsin completed a web-based survey. The survey included measures of prescriber satisfaction with delivering buprenorphine treatment and XR-naltrexone. In addition, the survey measured several prescriber characteristics and their perceptions of the organizational environment.

Results: Prescribers were generally satisfied with their work in delivering these two types of MOUD. Prescribers reporting a greater number of patients (r = .46, p = .006), those who would recommend the center to others (r = .56, p < .001), and those reporting positive relationships with staff (r = .56, p < .001) reported significantly greater overall satisfaction with delivering buprenorphine treatment. Prescribers who more strongly endorsed feeling overburdened reported lower overall buprenorphine satisfaction (r = -.37, p = .02). None of the prescriber characteristics or perceptions of the organizational environment were significantly associated with overall satisfaction with delivering XR-naltrexone treatment.

Conclusions: The generally high levels of satisfaction with both types of MOUD is notable given that prescriber dissatisfaction can lead to turnover and impact intentions to leave the profession. Future research should continue to explore the prescriber characteristics and organizational factors associated with satisfaction in providing different types of MOUD.

Registration: ClinicalTrials.gov. NCT02926482. Date of registration: September 9, 2016. https://clinicaltrials.gov/ct2/show/NCT02926482 .

References

Linzer M, Sinsky C, Poplau S, Brown R, Williams E . Joy In Medical Practice: Clinician Satisfaction In The Healthy Work Place Trial. Health Aff (Millwood). 2017; 36(10):1808-1814. DOI: 10.1377/hlthaff.2017.0790. View

Slavova S, Rock P, Bush H, Quesinberry D, Walsh S . Signal of increased opioid overdose during COVID-19 from emergency medical services data. Drug Alcohol Depend. 2020; 214:108176. PMC: 7351024. DOI: 10.1016/j.drugalcdep.2020.108176. View

Dick A, Pacula R, Gordon A, Sorbero M, Burns R, Leslie D . Growth In Buprenorphine Waivers For Physicians Increased Potential Access To Opioid Agonist Treatment, 2002-11. Health Aff (Millwood). 2015; 34(6):1028-34. PMC: 4743254. DOI: 10.1377/hlthaff.2014.1205. View

Andrilla C, Moore T, Patterson D . Overcoming Barriers to Prescribing Buprenorphine for the Treatment of Opioid Use Disorder: Recommendations from Rural Physicians. J Rural Health. 2018; 35(1):113-121. DOI: 10.1111/jrh.12328. View

Wainwright J, Mikre M, Whitley P, Dawson E, Huskey A, Lukowiak A . Analysis of Drug Test Results Before and After the US Declaration of a National Emergency Concerning the COVID-19 Outbreak. JAMA. 2020; 324(16):1674-1677. PMC: 7501585. DOI: 10.1001/jama.2020.17694. View

Volkow N, Frieden T, Hyde P, Cha S . Medication-assisted therapies--tackling the opioid-overdose epidemic. N Engl J Med. 2014; 370(22):2063-6. DOI: 10.1056/NEJMp1402780. View

DiMatteo M, Sherbourne C, Hays R, Ordway L, Kravitz R, McGlynn E . Physicians' characteristics influence patients' adherence to medical treatment: results from the Medical Outcomes Study. Health Psychol. 1993; 12(2):93-102. DOI: 10.1037/0278-6133.12.2.93. View

Alexander G, Stoller K, Haffajee R, Saloner B . An Epidemic in the Midst of a Pandemic: Opioid Use Disorder and COVID-19. Ann Intern Med. 2020; 173(1):57-58. PMC: 7138407. DOI: 10.7326/M20-1141. View

Morgan J, Schackman B, Weinstein Z, Walley A, Linas B . Overdose following initiation of naltrexone and buprenorphine medication treatment for opioid use disorder in a United States commercially insured cohort. Drug Alcohol Depend. 2019; 200:34-39. PMC: 6613830. DOI: 10.1016/j.drugalcdep.2019.02.031. View

10.

Shanafelt T, Boone S, Tan L, Dyrbye L, Sotile W, Satele D . Burnout and satisfaction with work-life balance among US physicians relative to the general US population. Arch Intern Med. 2012; 172(18):1377-85. DOI: 10.1001/archinternmed.2012.3199. View

11.

Huhn A, Dunn K . Why aren't physicians prescribing more buprenorphine?. J Subst Abuse Treat. 2017; 78:1-7. PMC: 5524453. DOI: 10.1016/j.jsat.2017.04.005. View

12.

Knudsen H, Brown R, Jacobson N, Horst J, Kim J, Collier E . Physicians' satisfaction with providing buprenorphine treatment. Addict Sci Clin Pract. 2019; 14(1):34. PMC: 6709557. DOI: 10.1186/s13722-019-0163-3. View

13.

Volkow N, Collins F . The Role of Science in Addressing the Opioid Crisis. N Engl J Med. 2017; 377(4):391-394. DOI: 10.1056/NEJMsr1706626. View

14.

Knudsen H, Lin L, Lofwall M . Adoption of the 275-patient buprenorphine treatment waiver for treating opioid use disorder: A state-level longitudinal analysis. Subst Abus. 2019; 41(2):259-268. PMC: 6954348. DOI: 10.1080/08897077.2019.1635959. View

15.

McMurray J, Williams E, Schwartz M, Douglas J, Van Kirk J, Konrad T . Physician job satisfaction: developing a model using qualitative data. SGIM Career Satisfaction Study Group. J Gen Intern Med. 1997; 12(11):711-4. PMC: 1497191. View

16.

Hall C, Brazil K, Wakefield D, Lerer T, Tennen H . Organizational culture, job satisfaction, and clinician turnover in primary care. J Prim Care Community Health. 2013; 1(1):29-36. DOI: 10.1177/2150131909360990. View

17.

Linn L, Brook R, Clark V, Davies A, Fink A, Kosecoff J . Physician and patient satisfaction as factors related to the organization of internal medicine group practices. Med Care. 1985; 23(10):1171-8. DOI: 10.1097/00005650-198510000-00006. View

18.

Jacobson N, Horst J, Wilcox-Warren L, Toy A, Knudsen H, Brown R . Organizational Facilitators and Barriers to Medication for Opioid Use Disorder Capacity Expansion and Use. J Behav Health Serv Res. 2020; 47(4):439-448. PMC: 7578054. DOI: 10.1007/s11414-020-09706-4. View

19.

Stein B, Gordon A, Dick A, Burns R, Pacula R, Farmer C . Supply of buprenorphine waivered physicians: the influence of state policies. J Subst Abuse Treat. 2014; 48(1):104-11. PMC: 4420477. DOI: 10.1016/j.jsat.2014.07.010. View

20.

Duncan A, Anderman J, Deseran T, Reynolds I, Stein B . Monthly Patient Volumes of Buprenorphine-Waivered Clinicians in the US. JAMA Netw Open. 2020; 3(8):e2014045. PMC: 7445589. DOI: 10.1001/jamanetworkopen.2020.14045. View